- Home
- SGLY vs TLPH Comparison
SGLY vs TLPH Comparison
Compare SGLY & TLPH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
N/A
N/A
Current Price
$1.16
Company Overview
Basic Information| Metric | SGLY | TLPH |
|---|---|---|
| Founded | 2001 | 2005 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 8.5M | 70.3M |
| IPO Year | 2008 | 2010 |
Fundamental Metrics
Financial Performance| Metric | SGLY | TLPH |
|---|---|---|
| Price | $1.20 | $1.16 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 1.3M | 162.7K |
| Earning Date | 05-15-2026 | 05-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 48.29 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | $1,813,193.00 | ★ $2,151,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $0.18 | $0.69 |
| 52 Week High | $8.65 | $1.57 |
Technical Indicators
Market Signals| Indicator | SGLY | TLPH |
|---|---|---|
| Relative Strength Index (RSI) | 37.15 | 43.64 |
| Support Level | $0.36 | $1.17 |
| Resistance Level | $8.65 | $1.29 |
| Average True Range (ATR) | 0.23 | 0.04 |
| MACD | -0.05 | 0.00 |
| Stochastic Oscillator | 4.12 | 18.18 |
Price Performance
Historical Comparison SGLY
TLPH
About SGLY Singularity Future Technology Ltd.
Singularity Future Technology Ltd is an investment holding company. The company's operating segment includes Freight Logistics Services and Sale of Crypto-mining Machines. It generates maximum revenue from the Freight Logistics Services segment. Geographically, it derives a majority of its revenue from China.
About TLPH Talphera Inc.
Talphera Inc. is a pharmaceutical company focused on the development and commercialization of therapies for use in medically supervised settings. The Company's nafamostat product candidates include Niyad and LTX-608. Its portfolio consists of nafamostat product candidates and pre-filled syringe product candidates.